ESTRO Multidisciplinary Management of Breast Cancer 2017

Absolute incidence of ipsilat breast recurrences*

Remarks

F-up (yr)

BCS BCS + RT

EORTC 10853 1

15

31% 18%

NSABP-17 2

17

35% 20%

SweDCIS 3

20

32% 20%

UK/ANZ 4

+/ - Tamoxifen

12

17% 2.6%

1 Donker et al JCO 2013 2 Wapnir et al JNCI 2011 3 Warnberg et al JCO 2014 4 Cuzick et al Lancet Oncol 2012

*: in all trials, about 50% of recurrences concerns an invasive recurrence